Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens

Prostate

Volumn 73, Issue 7, 2013, Pages 778-787

  Crawford, E David ^a   Rove, Kyle O ^a   Barqawi, Al B ^a   Maroni, Paul D ^a   Werahera, Priya N ^b   Baer, Craig A ^c   Koul, Hari K ^a   Rove, Cory A ^d   Lucia, M Scott ^b   La Rosa, Francisco G ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c BCSi Inc   (United States)

^d Wakely Consulting Group   (United States)

Author keywords

3D whole mount prostatectomy; Gleason score; prostate cancer; targeted focal therapy; transperineal mapping biopsy

Indexed keywords

ARTICLE; BRACHYTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; GLEASON SCORE; GOLD STANDARD; HISTOPATHOLOGY; HUMAN; IMAGE RECONSTRUCTION; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE VOLUME; PROSTATECTOMY; RETROSPECTIVE STUDY; SCORING SYSTEM; THREE DIMENSIONAL IMAGING; TRANSPERINEAL MAPPING BIOPSY; TRANSURETHRAL RESECTION;

AGED; HUMANS; IMAGE-GUIDED BIOPSY; IMAGING, THREE-DIMENSIONAL; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84876294696     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22622     Document Type: Article

References (28)

1. Ung JO, Richie JP, Chen MH, Renshaw AA, D'Amico AV,. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology 2002; 60: 458-463.
2. Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H,. Lead time and overdiagnosis in prostate-specific antigen screening: Importance of methods and context. J Natl Cancer Inst 2009; 101: 374-383.
3. Barry MJ,. Screening for prostate cancer-The controversy that refuses to die. N Engl J Med 2009; 360: 1351-1354.
4. Chun FK, Epstein JI, Ficarra V, Freedland SJ, Montironi R, Montorsi F, Shariat SF, Schröder FH, Scattoni V,. Optimizing performance and interpretation of prostate biopsy: A critical analysis of the literature. Eur Urol 2010; 58: 851-864.
5. Epstein JI, Walsh PC, Carter HB,. Importance of posterolateral needle biopsies in the detection of prostate cancer. Urology 2001; 57: 1112-1116.
6. Rabets J, Jones JS, Patel A, Zippe CD,. Prostate cancer detection with office-based saturation biopsy in a repeat biopsy population. J Urol 2004; 172: 94-97.
7. Andriole GL,. The lottery of conventional prostate biopsy. Nat Rev Urol 2009; 6: 188-189.
8. Jones JS,. Management of rising prostate-specific antigen following a negative biopsy. Cur Opin Urol 2010; 20: 198-203.
9. Onik G, Vaughan D, Lotenfoe R, Dineen M, Brady J,. The 'male lumpectomy': Focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up. Urol Oncol 2008; 26: 500-505.
10. Blana A, Murat FJ, Walter B, Thuroff S, Wieland WF, Chaussy C, Gelet A,. First analysis of the long-term results with transrectal HIFU in patients with localized prostate cancer. Eur Urol 2008; 53: 1194-1201.
11. Ahmed HU, Emberton M,. Benchmarks for success in focal therapy of prostate cancer: Cure or control ? World J Urol 2010; 28: 577-582.
12. Onik G, Miessau M, Bostwick DG,. Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J Clin Oncol 2009; 27: 4321-4326.
13. Barzell WE, Melamed MR,. Appropriate patient selection in the focal treatment of prostate cancer: The role of transperineal 3-dimensional pathologic mapping of the prostate-A 4-year experience. Urology 2007; 70: S27-S35.
14. Crawford ED, Wilson SS, Torkko KC, Hirano D, Stewart JS, Brammell C, Wilson RS, Kawata N, Sullivan H, Lucia MS, Werahera PN,. Clinical staging of prostate cancer: A computer-simulated study of transperineal prostate biopsy. BJU Int 2005; 96: 999-1004.
15. Hu Y, Ahmed HU, Carter T, Arumainayagam N, Lecornet E, Barzell W, Freeman A, Nevoux P, Hawkes DJ, Villers A, Emberton M, Barratt DC,. A biopsy simulation study to assess the accuracy of several transrectal ultrasonography (TRUS)-biopsy strategies compared with template prostate mapping biopsies in patients who have undergone radical prostatectomy. BJU Int 2012; 110: 812-820.
16. Barqawi AB, O'Donnell CI, Siomos VJ, Hou AH,. The effect of short-term dutasteride intake in early-stage prostate cancer: Analysis of 148 patients who underwent three-dimensional prostate mapping biopsy. Urology 2010; 76: 1067-1071.
17. Civantos F, Soloway MS, Pinto JE,. Histopathological effects of androgen deprivation in prostatic cancer. Semin Urol Oncol 1996; 14: 22-31.
18. Reuter VE,. Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology 1997; 49: 16-22.
19. Miller GJ, Cygan JM,. Morphology of prostate cancer: The effect of multifocality on histological grade, tumor volume and capsule penetration. J Urol 1994; 152: 1709-1713.
20. Westra WH, Hruban RH, Phelps TH, Isacson C,. editors. Surgical pathology dissection: An illustrated guide. 2nd edition. New York, NY: Springer-Verlag New York Inc.; 2003.
21. Gleason DF,. Histologic grading of prostate cancer: A perspective. Hum Pathol 1992; 23: 273-279.
22. Werahera PN, Miller GJ, Torkko K, Crawford ED, Stewart JS, Deantoni EP, Miller HL, Lucia MS,. Biomorphometric analysis of human prostatic carcinoma using three dimensional computer models. Hum Pathol 2004; 35: 798-807.
23. Walz J, Graefen M, Chun FK, Erbersdobler A, Haese A, Steuber T, Schlomm T, Huland H, Karakiewicz PI,. High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. Eur Urol 2006; 50: 498-505.
24. Barqawi AB, Rove KO, Gholizadeh S, O'Donnell CI, Koul H, Crawford ED,. The role of 3-dimensional mapping biopsy in decision making for treatment of apparent early-stage prostate cancer. J Urol 2011; 186: 80-85.
25. Abdollah F, Novara G, Briganti A, Scattoni V, Raber M, Roscigno M, Suardi N, Gallina A, Artibani W, Ficarra V, Cestari A, Guazzoni G, Rigatti P, Montorsi F,. Trans-rectal versus trans-perineal saturation rebiopsy of the prostate: Is there a difference in cancer detection rate ? Urology 2011; 77: 921-925.
26. Coogan CL, Latchamsetty KC, Greenfield J, Corman JM, Lynch B, Porter CR,. Increasing the number of biopsy cores improves the concordance of biopsy Gleason score to prostatectomy Gleason score. BJU Int 2005; 96: 324-327.
27. Cam K, Yucel S, Turkeri L, Akdas A,. Accuracy of transrectal ultrasound guided prostate biopsy: Histopathological correlation to matched prostatectomy specimens. Int J Urol 2002; 9: 257-260.
28. Sinnott M, Falzarano SM, Hernandez AV, Jones JS, Klein EA, Zhou M, Magi-Galluzzi C,. Discrepancy in prostate cancer localization between biopsy and prostatectomy specimens in patients with unilateral positive biopsy: Implications for focal therapy. Prostate 2012; 72 (11): 1179-1186.